Amol Akhade: Interlace trial shows OS benefit for advanced cervical cancer
Amol Akhade shared the following on LinkedIn:
“So finally it is published. The much-awaited Interlace trial for locally advanced cervical cancer shows 8% OS benefit at the end of 5 years for neoadjuvant chemo followed by CTRT vs CTRT alone. HR 0.60. Now how will you fit Keynote A18 into this? Pembrolizumab with CTRT did show OS benefit with HR of 0.67. What will you prefer for locally advanced cervical cancer in a patient eligible for both:
1. Interlace – neoadjuvant chemo followed by CTRT
2. Keynote A18 – pembrolizumab plus CTRT
3.Neoadjuvant chemo followed by Pembrolizumab plus CTRT
4.Only CTRT.
do participate in this survey on X
link below.”
More posts featuring Amol Akhade.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023